Infectious Diseases Drugs Markets : Market Research Report

Infectious Diseases Drugs Markets

Published: Oct. 1, 2009 - 244 Pages

1. Overview: 1.1 Statement of Report; 1.2 Scope of the Report; 1.3 Methodology; 1.4 Executive Summary
2. Clinical Syndromes and Therapy: 2.1 Head and Neck; 2.2 Eye; 2.3 Skin and Lymph Nodes; 2.4 Respiratory Tract; 2.5 Heart and Blood Vessels; 2.6 Gastrointestinal Tract, Liver and Abdomen; 2.7 Genitourinary Tract; 2.8 Nervous System; 2.9 Musculoskeletal System; 2.10 Human Immunodeficiency Virus (HIV) Infection; 2.11 Blood-borne Infections
3. Anti-infective Agent Markets: 3.1 FDA Approvals of New Anti-infective Therapy; 3.2 Anti-infective Agents in Current Pharmaceutical Developmental Programs; 3.3 Factors Determining Anti-infective Drug Development; 3.4 Pharmaceutical R&D Expenditures
4. Description of Anti-infective Therapeutic Agents: 4.1 Anti-bacterials; 4.2 Anti-virals; 4.3 Anti-fungals; 4.4 Vaccines
5. Market for Anti-infective Agents and Vaccines: 5.1 Molecular Diagnostics in Determining Demand
6. Decision-making Activity in the Anti-infective Market: 6.1 Net Present Value in Making Decisions to Develop and Market Antibiotics
7. Economics of Anti-microbial Drug Resistance: The Persistent need for Anti-bacterials: 7.1 Resistance and Antibiotic Usage
8. Global Market Analysis of Anti-infective Agents: 8.1 Market Size; 8.2 Market Share; 8.3 Market Drivers
9. Global Market for Anti-bacterial Therapies: 9.1 Amoxicillin; 9.2 Nafcillin; 9.3 Ticarcillin; 9.4 Imipenem; 9.5 Ceftriaxone; 9.6 Cefotetan; 9.7 Dalbavancin; 9.8 Doripenem
10. Global Market for Anti-fungal Therapies: 10.1 Amphotericin B; 10.2 Azoles; 10.3 Echinocandins; 10.4 Flucytosine
11. Global Market for Anti-viral Therapies: 11.1 Antiretroviral Market; 11.2 HCV Infections; 11.3 Acyclovir; 11.4 Adefovir; 11.5 Cidofovir; 11.6 Entecavir; 11.7 Fomivirsen; 11.8 Foscarnet; 11.9 Ganciclovir
12. Market, Demographic and Economic Trends: 12.1 Emerging Trends in Infectious Diseases Worldwide; 12.2 Global Burden of Infectious Disease; 12.3 The AIDS Model; 12.4 Dead-end Transmission of Zoonotic and Vector-borne Diseases; 12.5 Environmentally Persistent Organisms; 12.6 Old Microbes Cause New Disease; 12.7 Microbial Agents and Chronic Diseases; 12.8 Remerging and Resurging Infections; 12.9 Geographical Spread of Infectious Disease; 12.10 Drug-resistant Microbes; 12.11 Opportunistic Re-emerging Infections; 12.12 Re-emerging Zoonotic and Vector-borne Diseases; 12.13 Influenza; 12.14 Deliberately Emerging Infections; 12.15 Meeting the Challenge of Emerging Diseases
13. Political/Legal Trends: 13.1 AATF and Legislation; 13.2 Bioterrorism and Biowarfare
14. Technological Trends: 14.1 Anti-microbial Discovery in the Post-genomic Era
15. Socio-Cultural Trends
16. Competitive Landscape: 16.1 Introduction; 16.2 Strengths and Weaknesses in Anti-microbial Drug Discovery—Commercial; 16.3 Strengths and Weaknesses in Anti-microbial Drug Discovery—Academic; 16.4 Regulatory Hurdles; 16.5 Business Hurdles; 16.6 Strategic Alliances, Licensing Activity, and Mergers & Acquisitions in the Anti-infectives Landscape
17. Sales Performance amongst the Leading Players: Detailed Analysis of Leading Anti-infective Players: 17.1 GlaxoSmithKline; 17.2 Merck; 17.3 Pfizer; 17.4 Novartis; 17.5 Gilead Sciences; 17.6 Abbott; 17.7 Wyeth; 17.8 Sanofi-Aventis; 17.9 Bristol-Myers Squibb; 17.10 Johnson & Johnson; 17.11 Roche Pharma AG
18. Company Profiles: 18.1 Abraxis BioScience, Inc.; 18.2 Acambis; 18.3 Achillion Pharmaceuticals, Inc.; 18.4 Adlyfe, Inc.; 18.5 Advanced Life Sciences Holdings, Inc.; 18.6 Affinium Pharmaceuticals; 18.7 Akonni Biosystems; 18.8 Alnylam Pharmaceuticals; 18.9 APP Pharmaceuticals; 18.10 Aquapharm Biodiscovery; 18.11 Arbor Vita Corporation; 18.12 Arpida Ltd.; 18.13 Avexa Ltd.; 18.14 Basilea Pharmaceutica AG; 18.15 Baxter International, Inc.; 18.16 Biophage Pharma, Inc.; 18.17 CEL-SCI Corporation; 18.18 Cerexa, Inc. (Subsidiary of Forest Laboratories); 18.19 CombiMatrix Corporation; 18.20 Cubist Pharmaceuticals, Inc.; 18.21 Daiichi Sankyo Co., Ltd.; 18.22 Hospira, Inc.; 18.23 Incyte Corporation; 18.24 Idenix Pharmaceuticals, Inc.; 18.25 Medivir AB; 18.26 Meiji Holdings Co., Ltd.; 18.27 MerLion Pharmaceuticals; 18.28 Mutabilis; 18.29 NanoBio Corporation; 18.30 Nanosphere, Inc.; 18.31 Nanoviricides, Inc.; 18.32 Novabay Pharmaceuticals, Inc.; 18.33 Obetech, LLC; 18.34 Optimer Pharmaceuticals, Inc.; 18.35 Panacos Pharmaceuticals, Inc.; 18.36 Paratek Pharmaceuticals, Inc.; 18.37 Pharmasset, Inc.; 18.38 Pico Pharmaceuticals, Inc.; 18.39 PolyMedix, Inc.; 18.40 PowderMed Ltd. (Subsidiary of Pfizer); 18.41 Presidio Pharmaceuticals, Inc.; 18.42 Progenics Pharmaceuticals, Inc.; 18.43 Protez Pharmaceuticals (a Novartis Subsidiary); 18.44 Ribomed Biotechnologies, Inc.; 18.45 Rib-X Pharmaceuticals, Inc.; 18.46 Targanta Therapeutics Corporation, Inc.; 18.47 Theravance, Inc.; 18.48 Trius Therapeutics; 18.49 Vertex Pharmaceuticals, Inc.; 18.50 X-GEN Pharmaceuticals, Inc.; Appendix 1: FDA Compliance Policies Regarding Approved New Drug and Antibiotic Drug Products; Appendix 2: Anti-HCV Drugs in Development; Appendix 3: The Market for Anti-infectives in Animal Health; Appendix 4: Diagnostics for Infectious Agents
INDEX OF FIGURES: Figure 1.1: Leading Causes of Death in the U.S., 1958-2006; Figure 1.2: Global Distribution of Anti-infective Agent Sales by Geography; Figure 2.1: Incidence Rates of Invasive Methicillin-resistant S. aureus (MRSA) Infections by Age; Figure 2.2: U.S. Child Death Rate from Preventable Diseases, 2006; Figure 2.3: Infection Rate of Serotype 19A by Age Group in the U.S., 1998-2; Figure 2.4: U.S. Hospitalizations for Types of Respiratory Diseases in Children Under15 Years of Age, 2006; Figure 2.5: Economic Burden of Select Lung Diseases in the U.S., 2006; Figure 2.6: Infection Rate of Invasive Pneumococcal Disease in the U.S., 1998-2006; Figure 2.7: Status of H5N1 Avian Influenza, 2006; Figure 2.8: Number of Reported and Confirmed Cases of Influenza H1N1 Strain Worldwide, 2006; Figure 2.9: Distribution of H1N1 Flu in the U.S., August 2006; Figure 2.10: Novel H1N1 Confirmed and Probable Case Rate in the U.S., By Age Group; Figure 2.11: Number of Tuberculosis (TB) Cases among U.S. - and Foreign-born Persons, by Year Reported in the U.S., 1993-2006; Figure 2.12: Rate of Tuberculosis (TB) Cases among U.S. - and Foreign-born Persons, by Year Reported in the U.S., 1993-2006; Figure 2.13: Rate of Tuberculosis (TB) Cases by State/Area in the U.S., 2006 Figure 2.14: U.S.-born TB Cases by Ethnicity, 2006; Figure 2.15: Rate of New Hepatitis A, Hepatitis B and Hepatitis C Infections in; the U.S., 1982-2006; Figure 2.16: Countries Reporting Outbreaks of Cholera, 20066-2006; Figure 2.17: U.S. Rates of Sexually-Transmitted Diseases, 1940-2006; Figure 2.18: Rate of New Cases and Deaths of Cervical Cancer by Age Group Worldwide, 2006; Figure 2.19: Global Trend of HIV Infection, 1991-2006; Figure 2.20: Worldwide Percentage of Adults Living with HIV, 1990-2006; Figure 2.21: Worldwide Rate of New HIV Cases, 1990-2006; Figure 2.22: Percentage of Adult Population in African Countries with HIV, 2; Figure 2.23: Ethnic Distribution of AIDS Patients in the U.S., 2006; Figure 2.24: Ten Best Selling AIDS Drugs in the U.S., 2006; Figure 2.25: U.S. Rates for New HIV Cases, 2006; Figure 2.26: Global Malaria-Endemic Areas in the Eastern Hemisphere; Figure 2.27: Anti-Malarial Vaccine Pipeline, 2006; Figure 2.28: Global Anti-Malarial Drug Pipeline, 2006; Figure 2.29: West Nile Virus Activity in the U.S., 2006; Figure 3.1: Anti-infective Drug Market Projections, 20066-201; Figure 3.2: Leading Companies in Anti-infectives Market Share, 2006; Figure 3.3: Number of New Anti-bacterial Agents Approved by the FDA in the U.S., 1983-2006; Figure 3.4: Total Spending on Healthcare in the U.S., 1960-2006; Figure 3.5: Percentage Breakdown of U.S. Healthcare Spending, 2006; Figure 3.6: International per Capita Healthcare Spending by Country, 2006; Figure 3.7: Generic Drug Applications and Approvals in the U.S., 1995-2006; Figure 3.8: Savings Generated by Generic Use in the U.S., by Therapeutic Category, 1999-2006; Figure 3.9: Anti-bacterial and Anti-HIV New Molecular Entities (NMEs) Approved by the FDA, 1993-2006; Figure 3.10: Cost for New Drugs by Primary Indication, 2006; Figure 4.1: Market Share by Leading Anti-bacterial Drug Class; Figure 4.2: Anti-virals in the Marketplace, 2006; Figure 4.3: Anti-viral Market by Indication, Excluding HIV and HCV; Figure 4.4: Anti-viral Therapeutics Market, by Drug Class; Figure 4.5: Global Distribution of the Lack of Childhood Vaccination; Figure 4.6: GAVI Alliance Members; Figure 4.7: Global Vaccines Market, 2006; Figure 4.8: GlaxoSmithKline’s Vaccine Pipeline, 2006; Figure 4.9: The Vaccine Market by Geographical Area, 2006; Figure 5.1: Global Market for Molecular Diagnostics, 2002-2013; Figure 6.1: Number of Non-elderly Americans without Health Insurance Coverage, 1994-20067; Figure 6.2: Percentage of Non-elderly Americans without Health Insurance Coverage, 1994-20067; Figure 7.1: Global Multidrug Susceptibility in P. aeruginosa; Figure 7.2: Global Frequency of Vancomycin-resistant Enterococci, 2006; Figure 7.3: MRSA Trends According to Patient Location, 1998-20065; Figure 9.1: Projected Growth in Market for Injectable Anti-bacterials, 2008 and 2013; Figure 9.2: Real and Projected Market Shares for Major Anti-bacterial Classes,2008 and 2013; Figure 9.3: Frequency of S. aureus in Skin and Soft Tissue Infections; Figure 11.1: Current and Projected Market Size for Injectable Antiretrovirals by Class, 20068 and 2013; Figure 11.2: Market Share for Injectable Antiretrovirals by Drug Class, 2008; Figure 11.3: The Changing Face of the HCV Market: Growth and Projections by Drug Class, 20068 and 2013; Figure A3.1: Growth in Global Sales of Antibiotic Products in Animal Health, 2005-2012; Figure A4.1: FIND Pipeline for TB Diagnostics
INDEX OF TABLES: Table 1.1: Top Ten Causes of Death Worldwide; Table 1.2: Leading Pharmaceutical Companies in the Anti-infective Market—Total Global Sales, 2006; Table 2.1: Annual Rates of Global Infectious Diseases; Table 2.2: Drugs in Development for Chronic Hepatitis B, 2006; Table 2.3: Global HIV Statistics, 2006; Table 3.1: Top Selling Anti-infective Agents, 2006; Table 3.2: Sales for Leading Companies’ Infectious Diseases Segments, 2006; Table 3.3: Current Drug Development Times and Rates, by Therapeutic Indication; Table 3.4: Emerging Therapeutic Approaches; Table 3.5: New Drug Approvals in all Categories from FDA, 20060-2006; Table 3.6: Top Ten Global Pharmaceutical Markets, 2006; Table 3.7: BRIC countries, Percentage of GDP Spent on Healthcare, 2006; Table 3.8: Percentage of GDP Healthcare Spending by Country, 2006; Table 3.9: Top 20 Generic Drugs by Prescriptions, 2006; Table 3.10: Anti-bacterial Agents Undergoing Clinical Development; Table 3.11 Leading Tuberculosis R&D Candidates; Table 3.12: Pipeline for Repositioned Drugs; Table 4.1: Potential Anti-bacterial Protein Drug Targets; Table 4.2: In vitro Susceptibility of Staphylococci to New Agents in Development; Table 4.3: Anti-staphylococcal Vaccines and Immunoglobulins in the Late Stage Pipeline, 2006; Table 4.4: Bacterial Targets of Antibiotics and Resistance Mechanisms; Table 4.5: Guideline Summary for Antibiotic Selection for Skin and Soft Tissue Infections; Table 4.6: Selected Anti-viral Drugs; Table 4.7: Anti-reterovirals in Development, 2006; Table 4.8: New Types of HIV Drugs; Table 4.9: Recommended Daily Dosage of Seasonal Influenza Anti-viral Medications for Treatment and Chemoprophylaxis in the U.S., 20068-2006; Table 4.10: Percentage Drug Resistance for Common Influenza Virus Strains, 2; Table 4.11: Selected HCV Drugs in Development, 2006; Table 4.12: Therapeutic Agents in Development for Treating Hepatitis B, 2006; Table 4.13: Anti-fungal Compounds in Late Stage Development; Table 4.14: New Vaccines Licensed, 20065-2006; Table 4.15: Global Top Selling Blockbuster Vaccines, 2006; Table 4.16: Selected Anti-infective Monoclonal Antibodies in Clinical Development, 2006; Table 5.1: FDA-approved Commercial Kits for the Detection of Infectious Agents; Table 5.2: Examples of Personalized Medicine in Treatment of Infectious Disease; Table 6.1: Competitive Landscape for Anti-viral Drugs in Development, 20069; Table 6.2: Competitive Landscape for Anti-biotic Drugs in Development, 20069; Table 8.1 Anti-HIV Therapeutics Approved by the FDA; Table 9.1: Major Classes of Antibiotics; Table 10.1: Major Classes of Anti-fungals; Table 11.1: CCR-5 Receptor Agonists in Development, 20069; Table 12.1: Major Pathogens Identified in the Last 30 Years; Table 12.2: Emerging and Re-emerging Infectious Diseases and their Geographical Location; Table 16.1: Pharmaceutical Companies Ranked by Total R&D Expenditures, 20068; Table 16.2: International Regulatory Measures Indicated by the International Forum of Anti-bacterial Resistance; Table A2.1: Anti-HCV Pipeline, 20069; Table A3.1: U.S. Volume of Animal Health Antibiotics Used, 20060-20066; Table A3.2: European Sales of Animal Health Antibiotics, 20065-2012; Table A3.3: Use of Antibiotics as Growth Promotants; Table A4.1: The Market Structure for Infectious Disease Diagnostics; Table A4.2: Rapid Strep Tests on the Market; Table A4.3: Rapid Tests for Chlamydia; Table A4.4: Rapid Tests for Gonorrhea; Table A4.5: The Burden of Influenza; Table A4.6: Global Market Potential for TB Diagnostic Testing; Table A4.7: Global Market for HBV Diagnostic Testing; Table A4.8: U.S. Market for HBV Diagnostic Testing; Table A4.9: Serological Diagnosis of Hepatitis B Virus Infections; Table A4.10: Lower Detection Limits of HBV DNA Assays; Table A4.11: Summary of Hepatitis B Test Technology; Table A4.12: Global Market for HCV Diagnostic Testing; Table A4.13: Efficiency of Available HCV Screening Tests; Table A4.14: Recommendations for Diagnostic Testing for Hepatitis C 241

Abstract

According to the World Health Organization (WHO), six infectious diseases--pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS--account for half of all premature deaths worldwide, killing mostly children and young adults. What’s more, threatening pandemics such as swine flu (H1N1 influenza A virus) are adding significant pressure to already strained healthcare budgets of governments around the world. This report provides a detailed description of the current infectious diseases drugs market and highlights the existing and developing anti-infective agents used to ameliorate diseases’ afflictions on humankind. Anti-infective agents include: anti-viral therapeutics, antibiotics, anti-fungal agents and prophylactic treatments such as vaccines. Particular attention is paid to the clinical market segment and the pharmaceutical/biotechnology companies involved in anti-infective agents, with specific emphasis on each company’s sales focus, product portfolio and R&D pipeline. To date, the most successful anti-infective agents target the human immunodeficiency virus (HIV, the virus that causes AIDS), the herpes virus (HSV-1 and HSV-2), bacterial infections and hepatitis C (HCV). A number of exciting novel anti-viral and antibiotic compounds are currently revolutionizing the infectious diseases drugs market, including Truvada and Valtrex, which are anti-HIV and anti-herpes therapies, respectively. Significant resources are also being dedicated toward hepatitis A (HAV), hepatitis B (HBV) and Staph infections, including MRSA. What’s more, this study will examine the existing and developing anti-infective agents targeted at infectious diseases that continue to devastate developing countries, including: cholera, dengue fever, meningitis, rotavirus, typhoid, yellow fever and onchocerciasis (“river blindness”).

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Infectious Diseases Drugs Markets

Table of Contents

Abstract